Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 study in patients with refractory solid tumors.

Nektar technology is used in nine approved partnered products in the U.S. or Europe today, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.

This press release contains forward-looking statements that reflect management's current views regarding the progress and potential of the company's pipeline of proprietary drug candidates, the value and potential of the company's technology platform, and the company's position to enter into new strategic collaborations with third parties. These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage of development prior to regulatory approval for numerous reasons including, without limit
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ... validation from Intuitive Surgical, the manufacturer of ... Triton-36 Instrument Cleaning System. This approval reflects the ... in cleanliness currently in place for the sterile ... validation for reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... R.I. , March 6, 2015 Troyen ... Medical Officer of CVS Health (NYSE: CVS ... Health in Washington, D.C. today. ... critical role in addressing health care cost and quality ... After making CVS/pharmacy the first national pharmacy chain to ...
(Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2
... 2011 As the nation seeks to expand ... burdensome costs, researchers from Harvard University, Brigham and ... CVS ) reported that preventative health care may ... to expanded use of cost-effective generic medications for ...
... WOODCLIFF LAKE, N.J., July 6, 2011 Par Pharmaceutical Companies, ... will host a conference call and live webcast on Wednesday, ... for the second quarter 2011. The Company will release its ... Access to the live webcast can be made ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 2CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 3CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 4
(Date:3/6/2015)... 06, 2015 Ticket Down is a reputable ... at the Moda Center. After being away from ... is showing no signs of letting up on his “Garth ... and his wife, Trisha Yearwood, to venues around the United ... their critically acclaimed tour to the Moda Center in Portland, ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... Bakersfield, California (PRWEB) March 06, 2015 ... $5.7 million jury verdict on March 5, 2015 in ... County. According to court documents, a jury of 12 ... she suffered from being implanted with an Ethicon TVT ... of nine men and three women also awarded $5 ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Jvion, ... the release of a Clostridium Difficile (C Diff) ... The C Diff use case is the latest ... span hospital acquired infections, chronic conditions, and individual ... the C Diff solution flags at risk individuals ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... that absorbs blue light has been linked to sleep disorders in ... 1 issue of the journal Sleep . As this type ... insomnia. "The strong link between lens yellowing and age could ... said Line Kessel, M.D., Ph.D., the study,s lead author. In ...
... of the speech information rate of seven languages concludes ... which languages are spoken, but much less variation in ... "A cross-linguistic perspective on speech information rate," to be ... journal Language , is co-authored by Franois Pellegrino, ...
... HealthDay Reporter , WEDNESDAY, Aug. 31 (HealthDay ... records instead of paper files could greatly improve care ... "did better and improved faster" at various kinds of ... author Dr. Randall D. Cebul, a professor of medicine ...
... WEDNESDAY, Aug. 31 (HealthDay News) -- Some breast cancer patients ... can skip hormone therapy without increasing their risk of death, ... had tumors that were hormone-receptor positive, which means they require ... tumors is designed to starve the breast cancer cells by ...
... modified a toxic chemical produced by tiny marine microbes and ... Writing today in ACS Medicinal Chemistry Letters , UF ... of marine cyanobacteria and made it more specifically toxic ... of the compound to mice with a form of colon ...
... an easy way to improve your health: trust your neighbors. ... that increasing trust in neighbors is associated with better self-reported ... where one fits into the income distribution in their local ... self-rated health," said Eileen Bjornstrom, an assistant professor of sociology ...
Cached Medicine News:Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Language speed versus efficiency: Is faster better? 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 2Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 3Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 2Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 3Health News:Trust in your neighbors could benefit your health, MU study shows 2
RIA kit for Insulin (liquid phase separation)....
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
... The Helmer PC900 platelet ... to your laboratory counter top. ... smaller institution to have the ... temperature environment without taking up ...
Mini-Incubator PC100 is compact. It is the perfect solution for small institutions, mobile units, surgery rooms....
Medicine Products: